home-logo
Homepage /

GOBIVAZ®▼is the first biosimilar to the reference product (golimumab)

For prescribing information and adverse event reporting, click here

?
  • Same indications strengths and dosing schedules in adults across
    rheumatology, dermatology and gastroenterology, and in juvenile
    idiopathic arthritis (JIA) for children over 40kg*1,2
  • Same 50 mg and 100 mg strengths†, same dosing schedules1,2
  • Proven highly similar efficacy, safety/tolerability and immunogenicity3
  • Same homecare service provider†4 as the reference product, plus the
    choice of a different provider4
  • European manufacturing and supply chain assurance6,7
  • Manufactured using almost 100% renewable energy8
  • Latex-free injection design9

*GOBIVAZ® is registered in 50 mg and 100 mg strengths for subcutaneous administration.45 mg strength not available.

† SIMPONI® (golimumab)

 

 

References:

1. Gobivaz SmPCs available at https://www.medicines.org.uk/e... (Accessed Jan 26)
2. Simponi SmPCs available at https://www.medicines.org.uk/e... (Accessed Jan 2026)
3. Luque M, et al, Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double- Blind Study. BioDrugs. 2026 Jan;40(1):135-149. doi: 10.1007/s40259-025-00748-8.
4. Sciensus Homepage. Available at: https://www.sciensus.com/ (Last accessed Jan 2026)
5. Healthnet Homepage. Available at: https://www.healthnethomecare.... (Last accessed Jan 2026)
6. REF-GOLI-0002 DOP: GL/GOLI/NP/0015 September 2025.
7. Alvotech. Who we are.Available at: https://www.alvotech.com/who-w... (Last accessed Jan 2026)
8. Alvotech. Corporate sustainability. Environmental. Available at: https://www.alvotech.com/corpo...
sustainability/environmental (Last accessed Jan 2026).
9.Latex free statement for AVT05 DS/DP-PFS Number: R&D-REP-1629